ReviewClinical hypertension2020
Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?
Review in Clinical hypertension, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- The associations between fasting plasma glucose levels and mortality of COVID-19 in patients without diabetes.Diabetes research and clinical practice · 2020Trial
- Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia.The Korean journal of internal medicine · 2021Article
- Disaster hypertension and cardiovascular events in disaster and COVID-19 pandemic.Journal of clinical hypertension (Greenwich, Conn.) · 2021Review
- Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study.Journal of clinical hypertension (Greenwich, Conn.) · 2021Observational
- Investigating host-virus interaction mechanism and phylogenetic analysis of viral proteins involved in the pathogenesis.PloS one · 2021Article
- COVID-19 associated complications and potential therapeutic targets.European journal of pharmacology · 2020Review
- Does activation of the protective Renin-Angiotensin System have therapeutic potential in COVID-19?Molecular medicine (Cambridge, Mass.) · 2020Article
- Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain.Journal of clinical hypertension (Greenwich, Conn.) · 2020Observational
- ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives.Frontiers in molecular biosciences · 2020Review
- Pathophysiology of Cardiovascular Complications in COVID-19.Frontiers in physiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antihypertensive drugs are one of the most widely used pharmacologic agent in the world and it is predominantly used in the elderly subjects. Pneumonia is the most common cause of death in the extremely old subject. During infection and its complication such as sepsis, hypotension could be exacerbated by antihypertensive drugs because homeostasis mechanisms such as sodium balance, renin angiotensin aldosterone system and/or sympathetic nervous system can be mitigated by antihypertensive drug therapy. Severe Acute Respiratory Syndrome-Coronavirus-1 and 2 viral surface protein is known to attach angiotensin converting enzyme 2 (ACE2) on the cell membrane to facilitate viral entry into the cytoplasm. Despite the theoretical concerns of increased ACE2 expression by Renin-Angiotensin-Aldosterone system (RAS) blockade, there is no evidence that RAS inhibitors are harmful during COVID-19 infection and have in fact been shown to be beneficial in animal studies. Therefore, it is recommended to maintain RAS blockade during the current corona virus pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.